**Core Concept**
Etomidate is a short-acting intravenous anesthetic agent that acts as a non-selective GABA_A receptor agonist, producing sedation, hypnosis, and amnesia. Its unique pharmacological profile allows for its use in patients with cardiovascular instability.

**Why the Correct Answer is Right**
Etomidate's mechanism of action involves binding to the GABA_A receptor, enhancing the activity of the inhibitory neurotransmitter GABA. This leads to a decrease in neuronal excitability, resulting in sedation and hypnosis. Additionally, etomidate's minimal impact on cardiovascular function makes it an attractive option for patients with cardiovascular disease.

**Why Each Wrong Option is Incorrect**
**Option A:** Adrenal suppression is a known side effect of etomidate, particularly with long-term use. This is due to its inhibition of the enzyme 11-beta-hydroxylase, which is involved in the synthesis of cortisol. So, this option is incorrect as adrenal suppression is indeed a known effect of etomidate.

**Option B:** Myocardial depression is not a characteristic effect of etomidate. In fact, etomidate is often used in patients with cardiovascular instability due to its minimal impact on cardiovascular function. So, this option is incorrect as myocardial depression is not a known effect of etomidate.

**Option C:** Increased intracranial pressure (ICP) is not a characteristic effect of etomidate. In fact, etomidate may be used in patients with elevated ICP due to its ability to decrease cerebral metabolic rate and cerebral blood flow. So, this option is incorrect as increased ICP is not a known effect of etomidate.

**Clinical Pearl / High-Yield Fact**
Etomidate's use is often limited by its potential to cause adrenal suppression, particularly with long-term use. This is an important consideration when choosing an anesthetic agent for patients with pre-existing endocrine disorders.

**Correct Answer: A. Adrenal suppression**